Freenome strikes SPAC deal to go public in 2026
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated